AA
ACOR

AlphaMark Advisors’s Acorda Therapeutics ACOR Stock Holding History

AlphaMark Advisors’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-306
Closed -$691K – 520
2016
Q4 		$691K Hold
306
– – 0.36% 62
2016
Q3 		$767K Buy
306
+114
+59% +$340K 0.39% 65
2016
Q2 		$588K Hold
192
– – 0.35% 68
2016
Q1 		$610K Sell
192
-61
-24% -$253K 0.32% 64
2015
Q4 		$1.3M Buy
253
+70
+38% +$306K 0.66% 45
2015
Q3 		$583K Hold
183
– – 0.32% 66
2015
Q2 		$733K Buy
+183
New +$707K 0.41% 67

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CI
Cambiar Investors Denver, Colorado $2.3B AUM 24.77% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

AlphaMark Advisors's ACOR Position: Q1 2017 in Review

AlphaMark Advisors sold out of Acorda Therapeutics (ACOR) in Q1 2017, closing a stake of 306 shares — an estimated $691K sold.

AlphaMark Advisors first reported a position in ACOR in Q2 2015 and held it in 7 quarters. The position peaked at $1.3M in Q4 2015. 178 funds tracked by Wall St. Rank hold ACOR as of Q1 2017.

  • AlphaMark Advisors reported no remaining Acorda Therapeutics position as of Q1 2017 after selling out during the quarter.
  • AlphaMark Advisors sold 306 Acorda Therapeutics shares in Q1 2017, an estimated $691K.
  • AlphaMark Advisors first reported a position in Acorda Therapeutics in Q2 2015 and held it in 7 quarters.
  • AlphaMark Advisors's Acorda Therapeutics position peaked at $1.3M in Q4 2015.
  • 178 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2017.

Based on AlphaMark Advisors's 13F filing for Q1 2017, filed 9 May 2017.